Clinical Research Directory
Browse clinical research sites, groups, and studies.
Efficacy and Safety of Lusutrombopag After Allogeneic Hematopoietic Stem Cell Transplantation
Sponsor: The General Hospital of Western Theater Command
Summary
This study is an investigator-initiated prospective, single-center, open-label clinical trial designed to evaluate the clinical efficacy and safety of Lusutrombopag in promoting platelet remodeling after allogeneic hematopoietic stem cell transplantation in patients with hematologic disorders.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
45
Start Date
2026-01-13
Completion Date
2028-01-28
Last Updated
2026-03-25
Healthy Volunteers
No
Conditions
Interventions
Lusutrombopag
Lusutrombopag at a starting dose of 3 mg once daily. Treatment will continue for 2 weeks until CR is achieved, or treatment is discontinued after 14 days of continuous therapy, or when the discontinuation criteria are met. After the trial period plus 14 days, patients will be observed to determine if continued medication or regimen changes are necessary.
Locations (1)
The General Hospital of the People's Liberation Army
Chengdu, China